Aristotle Capital Boston LLC Buys 27,791 Shares of Novanta Inc. $NOVT

Aristotle Capital Boston LLC raised its stake in Novanta Inc. (NASDAQ:NOVT) by 18.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 176,676 shares of the technology company’s stock after acquiring an additional 27,791 shares during the period. Novanta comprises about 1.2% of Aristotle Capital Boston LLC’s investment portfolio, making the stock its 28th largest position. Aristotle Capital Boston LLC owned 0.49% of Novanta worth $21,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of NOVT. AQR Capital Management LLC grew its position in Novanta by 78.9% in the first quarter. AQR Capital Management LLC now owns 4,231 shares of the technology company’s stock valued at $537,000 after acquiring an additional 1,866 shares during the period. Goldman Sachs Group Inc. raised its position in Novanta by 1.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 419,037 shares of the technology company’s stock valued at $53,582,000 after purchasing an additional 6,533 shares during the last quarter. Jane Street Group LLC raised its position in Novanta by 1,762.5% in the 1st quarter. Jane Street Group LLC now owns 61,631 shares of the technology company’s stock valued at $7,881,000 after purchasing an additional 58,322 shares during the last quarter. First Trust Advisors LP bought a new position in Novanta in the 2nd quarter valued at $528,000. Finally, Amundi raised its position in Novanta by 2.0% in the 2nd quarter. Amundi now owns 18,042 shares of the technology company’s stock valued at $2,397,000 after purchasing an additional 347 shares during the last quarter. 98.35% of the stock is currently owned by institutional investors.

Novanta Trading Down 2.4%

NOVT stock opened at $151.43 on Thursday. The company has a market cap of $5.39 billion, a P/E ratio of 109.73 and a beta of 1.68. Novanta Inc. has a twelve month low of $98.27 and a twelve month high of $171.85. The company has a quick ratio of 2.69, a current ratio of 3.56 and a debt-to-equity ratio of 0.15. The business has a fifty day moving average of $145.35 and a 200-day moving average of $133.73.

Novanta (NASDAQ:NOVT) last released its earnings results on Monday, May 11th. The technology company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.03. The company had revenue of $257.71 million during the quarter, compared to the consensus estimate of $253.40 million. Novanta had a return on equity of 12.06% and a net margin of 5.35%.The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.74 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q2 2026 guidance at 0.810-0.860 EPS. As a group, equities research analysts expect that Novanta Inc. will post 3.59 EPS for the current year.

Insider Activity at Novanta

In related news, CEO Matthijs Glastra sold 7,500 shares of Novanta stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $150.43, for a total transaction of $1,128,225.00. Following the completion of the sale, the chief executive officer directly owned 42,761 shares of the company’s stock, valued at $6,432,537.23. The trade was a 14.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NOVT shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Novanta in a research report on Friday, April 17th. Robert W. Baird set a $180.00 price objective on Novanta in a research report on Tuesday, June 9th. Finally, Wall Street Zen downgraded Novanta from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $180.00.

Novanta Company Profile

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.